Treace Medical Concepts Reaffirms FY24 Revenue Guidance Of $201M - $211M, Est $205.405M
Portfolio Pulse from Benzinga Newsdesk
Treace Medical Concepts has reaffirmed its FY24 revenue guidance of $201M - $211M, with an estimated $205.405M. The company also expects Adjusted EBITDA to improve by approximately 50% compared to full-year 2023.
August 06, 2024 | 10:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Treace Medical Concepts has reaffirmed its FY24 revenue guidance of $201M - $211M, with an estimated $205.405M. The company also expects Adjusted EBITDA to improve by approximately 50% compared to full-year 2023.
Reaffirming revenue guidance and projecting a significant improvement in Adjusted EBITDA are positive indicators for Treace Medical Concepts. This suggests strong financial health and potential growth, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100